Although some patients demonstrate higher levels of minimal residual disease (MRD) at the end of induction therapy, their survival rates remain comparable to those of non-BCR/ABL1-like ALL patients (Arber et al., 2016; Roberts et al., 2014b). The gene discussed is BCR; the disease is acute lymphoblastic leukemia.